Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal

Table 2 Drug resistance genotyping and algorithmic switching results among HIV-2-infected Senegalese adults

Patient number	Viral load (copies/mL)	Visit to results (days)	Visit to switch (days)	RT resistance mutations	PR resistance mutations	Algorithm-specified regimen	Algorithm followed
10	378	56^a	-^a	-^a	-^a	-^a
26	359	58	-	-	-	No change	Yes
57	576	62	119	K65R, M184V	-	3TC, TDF, LPV/r, RAL	Yes
108	730	57	118	M184V	I50V	3TC, TDF, DRV/r, RAL	Yes
124	1439	71	-	-	-	No change	Yes
178	6774	118	153	M184I	-	3TC, TDF, LPV/r, RAL	Yes
569	222	126	-	-	-	No change	^b

3TC lamivudine, DRV/r ritonavir-boosted darunavir, TDF tenofovir disoproxil fumarate, LPV/r ritonavir-boosted lopinavir, RAL raltegravir
^aTest failed, no PCR products were obtained after using all available nucleic acid. In the absence of subsequent viral load testing and genotypic testing, this participant remained on existing regimen with enhanced adherence counseling
^bParticipant was lost to follow-up after genotyped visit

ISSN: 1745-6215